Current acetylcholinesterase-inhibitors: a neuroinformatics perspective

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Acetylcholinesterase (AChE) is a key neuroenzyme terminating neurotransmission by hydrolyzing acetylcholine.
• Dysregulation of acetylcholine levels is implicated in various neurological disorders.
• AChE inhibitors represent a significant therapeutic strategy for managing these conditions.

Purpose of the Study:

• To provide a concise update on acetylcholinesterase (AChE) inhibitors.
• To summarize molecular interactions, clinical applications, and limitations of various AChE inhibitors.
• To review traditional, novel, natural, and hybrid AChE inhibitors.

Main Methods:

• Literature review of existing research on AChE inhibitors.
• Analysis of molecular interactions and binding modes.
• Summary of clinical applications and therapeutic limitations.

Main Results:

• Covered traditional inhibitors (e.g., physostigmine, tacrine, donepezil, rivastigmine).
• Included novel inhibitors, physostigmine derivatives, and natural compounds (Huperzine A, B, Galangin).
• Discussed hybrid drugs and summarized current therapeutic applications.

Conclusions:

• AChE inhibitors encompass a diverse range of compounds with varying mechanisms and applications.
• Understanding molecular interactions is key to developing effective inhibitors.
• Continued research into novel and hybrid inhibitors holds promise for improved therapeutic outcomes.